Inderoâs Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8â12 weeks to â€3 days, and lowers costs, helping teams make informed go/no-go decisions faster.